The Scleroderma Research Foundation Monthly eNewsletter

eNews: December Edition

CONQUEST, a Platform Clinical Trial Developed by the SRF, Receives FDA OK to proceed

CONQUEST Featured in "Endpoints News"

SRF Chairman of the Board Luke Evnin, PhD, recently sat down with Andrew Dunn of "Endpoints News" to announce that CONQUEST has received FDA OK to proceed and share more about the specifics of this platform clinical trial:

"The study, called CONQUEST, has the support of two Big Pharma partners. Sanofi and Boehringer Ingelheim will test two of their top experimental drugs — amlitelimab and BI 1015550— and cover the trial’s estimated cost of $80 million, Evnin said. All told, he expects the first cycle of the study to enroll 400 scleroderma patients with interstitial lung disease, producing results in 2026."

Learn more about how the SRF is spurring scleroderma drug research by reading the full story.

You Helped Us Create a First-of-its-Kind Patient Registry, and It's Already Generating Results

In 2018, the SRF launched the CONQUER Registry (COllaborative National Quality and Efficacy Registry) – a first-of-its-kind longitudinal, nationwide patient registry and biosample repository aimed at improving care and developing more effective, personalized therapies for people living with systemic sclerosis (scleroderma). This innovative endeavor is possible thanks to generous contributions from our community of supporters, invaluable participants, and people like you.

Researchers have already published 6 papers based on the efforts and data of CONQUER, including two in the last year alone:

CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilization (2023)

The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation (2023) *

*Please note this link will download the article.

Through nationwide collaboration of researchers and people living with scleroderma, CONQUER will continue to generate more results. But the only way we can continue important scleroderma research projects like CONQUER is with your support. Will you join us in the search for a cure by making a tax-deductible gift today?

Lorena's Journey with Scleroderma

Lorena was diagnosed with scleroderma in 2021, and she wants a cure found for this disease.

“When I went to see my scleroderma doctor for the first time, I was in a wheelchair…I was unable to walk long distance due to joint stiffness, pain, and shortness of breath,” says Lorena. Today, things are different. “With the help of all my doctors, I’m in a better place now.”

And this is why research matters to Lorena—because research is what enables her doctors to suggest better treatments and strategies to help her manage her scleroderma. Ultimately, Lorena looks to research “to find a cure for the disease so that no one else has to go through this debilitating condition.”

Thank you, Lorena, for sharing your story and experiences. We will continue to put research at the center of everything we do, for you and for everyone who is affected by scleroderma.

Why Dr. Chang Chose Scleroderma Research

What makes researchers so dedicated to finding a cure? SRF-Funded investigator, Dr. Howard Chang of Stanford University, shares his perspective on making an impact through scleroderma research.

Happy Holidays from Your Friends at the SRF

This holiday season, we're wishing you and your loved ones good health and joy! Your incredible support keeps us motivated to stay completely focused on finding a cure. However you decide to celebrate, we hope your days are packed with love and peace. We're truly thankful for everything you do!

Research is at the center of all we do to find a cure.

Ways to Support Research

Employer Matching / Planned Giving